Article
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Advances in therapy - 1 Jun 2021
Forns Xavier, Feld Jordan J, Dylla Douglas E, Pol Stanislas, Chayama Kazuaki, Hou Jinlin, Heo Jeong, Lampertico Pietro, Brown Ashley, Bondin Mark, Tatsch Fernando, Burroughs Margaret, Marcinak John, Zhang Zhenzhen, Emmett Amanda, Gordon Stuart C, Jacobson Ira M
Abstract excerpt
INTRODUCTION: More than 70 million people are estimated to be infected with hepatitis C virus (HCV) globally. If left untreated, HCV infection can lead to complications such as extensive liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evolution of treatments has resulted in highly effective and well-tolerated all-oral direct-acting antivirals. The pangenotypic regimen of glecaprevir/pibrentasvir is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.